Use of biologics in non‐infectious uveitis: the situation in northern England

Biologic therapy for uveitis: addressing access issues is paramount

“…In both active and inactive noninfectious intermediate uveitis, posterior uveitis or panuveitis two large well designed multinational clinical trials of adalimumab have been published demonstrating its efficacy. 3,4 Other trials are underway, for example, of baricitinib (a funded therapy for rheumatoid arthritis) and adalimumab in uveitis (Clinicaltrials.gov NCT04088409). However, in the Australian and New Zealand single payer systems, a crucial part of facilitating patient access is being funded by the central pharmaceutical scheme (Pharmaceutical Benefits Scheme and Pharmac respectively).…”